Scarica l'app Stockscreener
0.8723
4.42%
-0.0401
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.9124
Aprire:
$0.93
Volume 24 ore:
786.88K
Relative Volume:
0.36
Capitalizzazione di mercato:
$164.69M
Reddito:
$154.90M
Utile/perdita netta:
$-20.20M
Rapporto P/E:
-7.239
EPS:
-0.1205
Flusso di cassa netto:
$-27.91M
1 W Prestazione:
-27.93%
1M Prestazione:
-8.84%
6M Prestazione:
-20.72%
1 anno Prestazione:
-53.36%
Intervallo 1D:
$0.8701
$0.9343
Intervallo di 1 settimana:
$0.8714
$1.09
Portata 52W:
$0.7362
$2.30
Heron Therapeutics Inc Stock (HRTX) Company Profile
Nome
Heron Therapeutics Inc
Settore
Industria
Telefono
(858) 251-4400
Indirizzo
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
0.8701 | 173.08M | 154.90M | -20.20M | -27.91M | -0.1205 |
VRTX
Vertex Pharmaceuticals Inc
|
440.56 | 114.99B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
697.19 | 75.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.52 | 49.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.10 | 38.92B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.10 | 31.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-09 | Iniziato | H.C. Wainwright | Buy |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2024-04-23 | Iniziato | CapitalOne | Overweight |
| 2024-03-13 | Reiterato | Needham | Buy |
| 2020-05-27 | Iniziato | Guggenheim | Buy |
| 2020-02-20 | Reiterato | Needham | Buy |
| 2019-01-16 | Reiterato | Needham | Buy |
| 2018-04-05 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Reiterato | Mizuho | Buy |
| 2018-03-01 | Reiterato | Needham | Buy |
| 2018-01-03 | Iniziato | Leerink Partners | Outperform |
| 2017-09-27 | Iniziato | Northland Capital | Outperform |
| 2017-02-27 | Iniziato | Needham | Buy |
| 2016-10-26 | Iniziato | Aegis Capital | Buy |
| 2016-09-06 | Ripresa | Lake Street | Buy |
| 2016-05-03 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-10 | Iniziato | Lake Street | Buy |
| 2015-09-23 | Reiterato | Leerink Partners | Outperform |
| 2015-09-02 | Iniziato | BofA/Merrill | Buy |
| 2015-08-03 | Reiterato | Brean Capital | Buy |
| 2015-06-30 | Reiterato | JMP Securities | Mkt Outperform |
| 2015-06-19 | Reiterato | Leerink Partners | Outperform |
| 2014-08-07 | Iniziato | Noble Financial | Buy |
Mostra tutto
Heron Therapeutics Inc Borsa (HRTX) Ultime notizie
Heron Therapeutics (HRTX) price target decreased by 15.38% to 3.74 - MSN
Acute care revenue growth helps Heron (HRTX) reaffirm 2026 guidance despite Q1 sales decline - MSN
Heron outlines $173M-$183M 2026 net product sales outlook as it targets return to positive adjusted EBITDA - MSN
Adage Capital amendment shows 0% ownership in Heron Therapeutics (HRTX) - Stock Titan
Heron Therapeutics (HRTX) Quarterly Loss Revives Dilution Fears And Tests Profitability Narrative - Sahm
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Heron Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2026 Earnings Call Transcript - Insider Monkey
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
Needham Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $3 - Moomoo
H.C. Wainwright cuts Heron Therapeutics stock price target on weak Q1 results - Investing.com
TradingKey - TradingKey
Heron (HRTX) Q1 2026 Earnings Call Transcript - AOL.com
Heron Therapeutics Backs 2026 Rev $173M-$183M >HRTX - Moomoo
Heron Therapeutics Inc (HRTX) Q1 2026 Earnings Call Highlights: Resilient Growth Amidst Challenges By GuruFocus - Investing.com Canada
Heron Therapeutics Q1 earnings call highlights - MSN
Heron Therapeutics Faces Tight Covenant Constraints That Threaten Liquidity and Strategic Flexibility - TipRanks
Heron Therapeutics 1Q Loss/Shr 4c >HRTX - Moomoo
Heron Therapeutics Signals Recovery Despite Soft Q1 - TipRanks
Heron Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Heron Therapeutics, Inc. Form 10-Q: Financial Results, Forward-Looking Statements, and Key Risks for Q1 2026 - Minichart
Heron Therapeutics (NASDAQ:HRTX) Releases Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Heron Therapeutics, Inc. Reaffirms Earnings Guidance for the Full Year 2026 - marketscreener.com
Heron Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Heron Therapeutics (HRTX) reports Q1 loss, lags revenue estimates - MSN
Heron Therapeutics Q1 Earnings Call Highlights - MarketBeat
Acute Care Revenue Growth Helps Heron (HRTX) Reaffirm 2026 Guidance Despite Q1 Sales Decline - Yahoo Finance
Heron Therapeutics Reports Q1 2026 Results: 32% Acute Care Revenue Growth, Reaffirms 2026 Guidance - Minichart
HRTX: Q1 sales reached $34.7M, rebounding in March, with strong growth and full-year guidance reaffirmed - TradingView
HRTX: Q1 sales hit $34.7M, acute care up 32% YoY, guidance reaffirmed, and commercial expansion planned - TradingView
Heron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Earnings call transcript: Heron Therapeutics Q1 2026 results miss forecasts, stock drops - Investing.com Canada
Heron Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Heron Therapeutics Q1 Results Miss, but Acute Care Growth and Reaffirmed Outlook Support HRTX - ChartMill
Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Heron Therapeutics Q1 2026 earnings preview - MSN
Heron Therapeutics' Q1 revenue falls as oncology sales drop - TradingView
HERON THERAPEUTICS, INC. /DE/ 1Q 2026: Revenue $34.7M, EPS $(0.04) — 10-Q Summary - TradingView
Heron Therapeutics: Q1 Earnings Snapshot - kare11.com
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance - The Manila Times
BRIEF-Heron Therapeutics Q1 EPS USD -0.04 - TradingView
Heron Therapeutics (HRTX) swings to Q1 2026 loss as oncology sales fall and interest costs rise - Stock Titan
[8-K] HERON THERAPEUTICS, INC. /DE/ Reports Material Event - Stock Titan
MSN Money - MSN
Heron Therapeutics Inc expected to post a loss of 1 cent a shareEarnings Preview - TradingView
Earnings Preview: HRTX to Report Financial Results Pre-market on May 11 - Moomoo
Heron Therapeutics (HRTX) COO acquires 125,000 shares via RSU exercise - Stock Titan
Analysts estimate Heron Therapeutics (HRTX) to report a decline in earnings: What to look out for - MSN
Heron Therapeutics (HRTX) COO gains 11,770 shares through RSU conversion - Stock Titan
Heron EVP exercises RSUs into 23,464 common shares | HRTX Insider Trading - Stock Titan
Heron Therapeutics Inc Azioni (HRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Heron Therapeutics Inc Azioni (HRTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Morgan Adam | Director |
Aug 08 '25 |
Buy |
1.50 |
1,766,546 |
2,649,819 |
8,753,290 |
0.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):